{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T07:31:42Z","timestamp":1794727902217,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013699","name":"Ohio State University Comprehensive Cancer Center\u2014Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009960","name":"American Association of Endocrine Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014285","name":"Society of University Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA277083"],"award-info":[{"award-number":["R21CA277083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adrenocortical carcinoma (ACC) has a poor prognosis, and no new drugs have been identified in decades. The absence of drug development can partly be attributed to a lack of preclinical models. Both animal models and 2D cell cultures of ACC fail to accurately mimic the disease, as animal physiology is inherently different than humans, and 2D cultures fail to represent the crucial 3D architecture. Organoids and other small 3D in vitro models of tissues or tumors can model certain complexities of human in vivo biology; however, this technology has largely yet to be applied to ACC. In this study, we describe the generation of 3D tumor constructs from an established ACC cell line, NCI-H295R. NCI-H295R cells were encapsulated to generate 3D ACC constructs. Tumor constructs were assessed for biomarker expression, viability, proliferation, and cortisol production. In addition, matrix metalloproteinase (MMP) functionality was assessed directly using fluorogenic MMP-sensitive biosensors and through infusion of NCI-H295R cells into a metastasis-on-a-chip microfluidic device platform. ACC tumor constructs showed expression of biomarkers associated with ACC, including SF-1, Melan A, and inhibin \u03b1. Treatment of ACC tumor constructs with chemotherapeutics demonstrated decreased drug sensitivity compared to 2D cell culture. Since most tumor cells migrate through tissue using MMPs to break down extracellular matrix, we validated the utility of ACC tumor constructs by integrating fluorogenic MMP-sensitive peptide biosensors within the tumor constructs. Lastly, in our metastasis-on-a-chip device, NCI-H295R cells successfully engrafted in a downstream lung cell line-based construct, but invasion distance into the lung construct was decreased by MMP inhibition. These studies, which would not be possible using 2D cell cultures, demonstrated that NCI-H295R cells secreted active MMPs that are used for invasion in 3D. This work represents the first evidence of a 3D tumor constructs platform for ACC that can be deployed for future mechanistic studies as well as development of new targets for intervention and therapies.<\/jats:p>","DOI":"10.1038\/s41598-023-42659-0","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T08:02:15Z","timestamp":1695110535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity"],"prefix":"10.1038","volume":"13","author":[{"given":"Priya H.","family":"Dedhia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemamylammal","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie G.","family":"Nairon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Zent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila V.","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Leight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Skardal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"42659_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282\u2013326. https:\/\/doi.org\/10.1210\/er.2013-1029 (2014).","journal-title":"Endocr. Rev."},{"key":"42659_CR2","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/cam4.2474","volume":"8","author":"H Dillekas","year":"2019","unstructured":"Dillekas, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases?. Cancer Med. 8, 5574\u20135576. https:\/\/doi.org\/10.1002\/cam4.2474 (2019).","journal-title":"Cancer Med."},{"key":"42659_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.aaf2784","volume":"352","author":"S Turajlic","year":"2016","unstructured":"Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169\u2013175. https:\/\/doi.org\/10.1126\/science.aaf2784 (2016).","journal-title":"Science"},{"key":"42659_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1530\/ERC-17-0447","volume":"25","author":"K Kiseljak-Vassiliades","year":"2018","unstructured":"Kiseljak-Vassiliades, K. et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr. Relat. Cancer 25, 437\u2013451. https:\/\/doi.org\/10.1530\/ERC-17-0447 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"42659_CR5","first-page":"5488","volume":"50","author":"AF Gazdar","year":"1990","unstructured":"Gazdar, A. F. et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50, 5488\u20135496 (1990).","journal-title":"Cancer Res."},{"key":"42659_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/bit.25950","volume":"113","author":"A Skardal","year":"2016","unstructured":"Skardal, A., Devarasetty, M., Forsythe, S., Atala, A. & Soker, S. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol. Bioeng. 113, 2020\u20132032. https:\/\/doi.org\/10.1002\/bit.25950 (2016).","journal-title":"Biotechnol. Bioeng."},{"key":"42659_CR7","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1007\/s10439-015-1298-3","volume":"43","author":"A Skardal","year":"2015","unstructured":"Skardal, A., Devarasetty, M., Rodman, C., Atala, A. & Soker, S. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. Ann. Biomed. Eng. 43, 2361\u20132373. https:\/\/doi.org\/10.1007\/s10439-015-1298-3 (2015).","journal-title":"Ann. Biomed. Eng."},{"key":"42659_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht, M. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol. 16, 426\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1 (2015).","journal-title":"Lancet Oncol."},{"key":"42659_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/biology3020345","volume":"3","author":"CJ Lovitt","year":"2014","unstructured":"Lovitt, C. J., Shelper, T. B. & Avery, V. M. Advanced cell culture techniques for cancer drug discovery. Biology (Basel) 3, 345\u2013367. https:\/\/doi.org\/10.3390\/biology3020345 (2014).","journal-title":"Biology (Basel)"},{"key":"42659_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1152\/physiol.00036.2016","volume":"32","author":"K Duval","year":"2017","unstructured":"Duval, K. et al. Modeling physiological events in 2D vs. 3D cell culture. Physiology (Bethesda) 32, 266\u2013277. https:\/\/doi.org\/10.1152\/physiol.00036.2016 (2017).","journal-title":"Physiology (Bethesda)"},{"key":"42659_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cell.2007.08.006","volume":"130","author":"KM Yamada","year":"2007","unstructured":"Yamada, K. M. & Cukierman, E. Modeling tissue morphogenesis and cancer in 3D. Cell 130, 601\u2013610. https:\/\/doi.org\/10.1016\/j.cell.2007.08.006 (2007).","journal-title":"Cell"},{"key":"42659_CR12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers, H. Modeling development and disease with organoids. Cell 165, 1586\u20131597. https:\/\/doi.org\/10.1016\/j.cell.2016.05.082 (2016).","journal-title":"Cell"},{"key":"42659_CR13","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19732","volume":"5","author":"BR Dye","year":"2016","unstructured":"Dye, B. R. et al. A bioengineered niche promotes in vivo engraftment and maturation of pluripotent stem cell derived human lung organoids. Elife 5, e19732. https:\/\/doi.org\/10.7554\/eLife.19732 (2016).","journal-title":"Elife"},{"key":"42659_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1053\/j.gastro.2015.12.042","volume":"150","author":"PH Dedhia","year":"2016","unstructured":"Dedhia, P. H., Bertaux-Skeirik, N., Zavros, Y. & Spence, J. R. Organoid models of human gastrointestinal development and disease. Gastroenterology 150, 1098\u20131112. https:\/\/doi.org\/10.1053\/j.gastro.2015.12.042 (2016).","journal-title":"Gastroenterology"},{"key":"42659_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1242\/dev.138453","volume":"144","author":"YH Tsai","year":"2017","unstructured":"Tsai, Y. H. et al. In vitro patterning of pluripotent stem cell-derived intestine recapitulates in vivo human development. Development 144, 1045\u20131055. https:\/\/doi.org\/10.1242\/dev.138453 (2017).","journal-title":"Development"},{"key":"42659_CR16","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1016\/j.biomaterials.2012.03.034","volume":"33","author":"A Skardal","year":"2012","unstructured":"Skardal, A. et al. Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function. Biomaterials 33, 4565\u20134575. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.03.034 (2012).","journal-title":"Biomaterials"},{"key":"42659_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21200-8","volume":"8","author":"AR Mazzocchi","year":"2018","unstructured":"Mazzocchi, A. R., Rajan, S. A. P., Votanopoulos, K. I., Hall, A. R. & Skardal, A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci. Rep. 8, 2886. https:\/\/doi.org\/10.1038\/s41598-018-21200-8 (2018).","journal-title":"Sci. Rep."},{"key":"42659_CR18","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/ab6d36","volume":"12","author":"A Skardal","year":"2020","unstructured":"Skardal, A. et al. Drug compound screening in single and integrated multi-organoid body-on-a-chip systems. Biofabrication 12, 025017. https:\/\/doi.org\/10.1088\/1758-5090\/ab6d36 (2020).","journal-title":"Biofabrication"},{"key":"42659_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08879-x","volume":"7","author":"A Skardal","year":"2017","unstructured":"Skardal, A. et al. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci. Rep. 7, 8837 (2017).","journal-title":"Sci. Rep."},{"key":"42659_CR20","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3892\/or.2015.3767","volume":"33","author":"Y Imamura","year":"2015","unstructured":"Imamura, Y. et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol. Rep. 33, 1837\u20131843. https:\/\/doi.org\/10.3892\/or.2015.3767 (2015).","journal-title":"Oncol. Rep."},{"key":"42659_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1242\/jcs.188102","volume":"130","author":"A Riedl","year":"2017","unstructured":"Riedl, A. et al. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J. Cell Sci. 130, 203\u2013218. https:\/\/doi.org\/10.1242\/jcs.188102 (2017).","journal-title":"J. Cell Sci."},{"key":"42659_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"F Hirschhaeuser","year":"2010","unstructured":"Hirschhaeuser, F. et al. Multicellular tumor spheroids: An underestimated tool is catching up again. J. Biotechnol. 148, 3\u201315. https:\/\/doi.org\/10.1016\/j.jbiotec.2010.01.012 (2010).","journal-title":"J. Biotechnol."},{"key":"42659_CR23","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1096\/fj.201801028RR","volume":"33","author":"G Poli","year":"2019","unstructured":"Poli, G. et al. Human fetal adrenal cells retain age-related stem- and endocrine-differentiation potential in culture. FASEB J. 33, 2263\u20132277. https:\/\/doi.org\/10.1096\/fj.201801028RR (2019).","journal-title":"FASEB J."},{"key":"42659_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2021.09.01.458584","author":"J Aleman","year":"2021","unstructured":"Aleman, J. et al. Engineering a thixotropic and biochemically tunable hyaluronan and. bioRxiv https:\/\/doi.org\/10.1101\/2021.09.01.458584 (2021).","journal-title":"bioRxiv"},{"key":"42659_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bprint.2019.e00058","volume":"16","author":"CC Clark","year":"2019","unstructured":"Clark, C. C., Aleman, J., Mutkus, L. & Skardal, A. A mechanically robust thixotropic collagen and hyaluronic acid bioink supplemented with gelatin nanoparticles. Bioprinting 16, e00058 (2019).","journal-title":"Bioprinting"},{"key":"42659_CR26","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/aae543","volume":"11","author":"A Mazzocchi","year":"2018","unstructured":"Mazzocchi, A., Devarasetty, M., Huntwork, R., Soker, S. & Skardal, A. Optimization of collagen type I-hyaluronan hybrid bioink for 3D bioprinted liver microenvironments. Biofabrication 11, 015003. https:\/\/doi.org\/10.1088\/1758-5090\/aae543 (2018).","journal-title":"Biofabrication"},{"key":"42659_CR27","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/ac45eb","author":"A Mazzocchi","year":"2021","unstructured":"Mazzocchi, A. et al. Exploiting maleimide-functionalized hyaluronan hydrogels to test cellular responses to physical and biochemical stimuli. Biomed. Mater. https:\/\/doi.org\/10.1088\/1748-605X\/ac45eb (2021).","journal-title":"Biomed. Mater."},{"key":"42659_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.actbio.2020.02.015","volume":"106","author":"SAP Rajan","year":"2020","unstructured":"Rajan, S. A. P. et al. Probing prodrug metabolism and reciprocal toxicity with an integrated and humanized multi-tissue organ-on-a-chip platform. Acta Biomater. 106, 124\u2013135. https:\/\/doi.org\/10.1016\/j.actbio.2020.02.015 (2020).","journal-title":"Acta Biomater."},{"key":"42659_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.actbio.2015.07.030","volume":"25","author":"A Skardal","year":"2015","unstructured":"Skardal, A. et al. A hydrogel bioink toolkit for mimicking native tissue biochemical and mechanical properties in bioprinted tissue constructs. Acta Biomater. 25, 24\u201334. https:\/\/doi.org\/10.1016\/j.actbio.2015.07.030 (2015).","journal-title":"Acta Biomater."},{"key":"42659_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/mi11020208","author":"E Maloney","year":"2020","unstructured":"Maloney, E. et al. Immersion bioprinting of tumor organoids in multi-well plates for increasing chemotherapy screening throughput. Micromachines (Basel) https:\/\/doi.org\/10.3390\/mi11020208 (2020).","journal-title":"Micromachines (Basel)"},{"key":"42659_CR31","doi-asserted-by":"publisher","DOI":"10.1063\/1.5056188","volume":"6","author":"A Mazzocchi","year":"2019","unstructured":"Mazzocchi, A., Soker, S. & Skardal, A. 3D bioprinting for high-throughput screening: Drug screening, disease modeling, and precision medicine applications. Appl. Phys. Rev. 6, 011302 (2019).","journal-title":"Appl. Phys. Rev."},{"key":"42659_CR32","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1245\/s10434-020-08351-7","volume":"27","author":"KI Votanopoulos","year":"2020","unstructured":"Votanopoulos, K. I. & Skardal, A. ASO author reflections: Co-cultured lymph node and tumor organoids as a platform for the creation of adaptive immunity and predict response to immunotherapy. Ann. Surg. Oncol. 27, 1968\u20131969. https:\/\/doi.org\/10.1245\/s10434-020-08351-7 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"42659_CR33","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1245\/s10434-019-08143-8","volume":"27","author":"KI Votanopoulos","year":"2020","unstructured":"Votanopoulos, K. I. et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: Feasibility study. Ann. Surg. Oncol. 27, 1956\u20131967. https:\/\/doi.org\/10.1245\/s10434-019-08143-8 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"42659_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-018-7008-2","volume":"26","author":"KI Votanopoulos","year":"2019","unstructured":"Votanopoulos, K. I. et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: A feasibility study. Ann. Surg. Oncol. 26, 139\u2013147. https:\/\/doi.org\/10.1245\/s10434-018-7008-2 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"42659_CR35","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1021\/acsbiomaterials.8b01356","volume":"5","author":"A Mazzocchi","year":"2019","unstructured":"Mazzocchi, A. et al. Pleural effusion aspirate for use in 3D lung cancer modeling and chemotherapy screening. ACS Biomater. Sci. Eng. 5, 1937\u20131943. https:\/\/doi.org\/10.1021\/acsbiomaterials.8b01356 (2019).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"42659_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-019-02269-2","author":"S Forsythe","year":"2019","unstructured":"Forsythe, S. et al. Development of a colorectal cancer 3D micro-tumor construct platform from cell lines and patient tumor biospecimens for standard-of-care and experimental drug screening. Ann. Biomed. Eng. https:\/\/doi.org\/10.1007\/s10439-019-02269-2 (2019).","journal-title":"Ann. Biomed. Eng."},{"key":"42659_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccell.2016.07.013","volume":"30","author":"S Zheng","year":"2016","unstructured":"Zheng, S. et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 30, 363. https:\/\/doi.org\/10.1016\/j.ccell.2016.07.013 (2016).","journal-title":"Cancer Cell"},{"key":"42659_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"Giordano, T. J. et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 162, 521\u2013531. https:\/\/doi.org\/10.1016\/S0002-9440(10)63846-1 (2003).","journal-title":"Am. J. Pathol."},{"key":"42659_CR39","first-page":"6762","volume":"61","author":"C Gicquel","year":"2001","unstructured":"Gicquel, C. et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 61, 6762\u20136767 (2001).","journal-title":"Cancer Res."},{"key":"42659_CR40","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier, F. et al. Mutations of beta-catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65, 7622\u20137627. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0593 (2005).","journal-title":"Cancer Res."},{"key":"42659_CR41","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","volume":"70","author":"B Ragazzon","year":"2010","unstructured":"Ragazzon, B. et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 70, 8276\u20138281. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2014 (2010).","journal-title":"Cancer Res."},{"key":"42659_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1677\/erc.1.1315","volume":"15","author":"L Cerquetti","year":"2008","unstructured":"Cerquetti, L. et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr. Relat. Cancer 15, 623\u2013634. https:\/\/doi.org\/10.1677\/erc.1.1315 (2008).","journal-title":"Endocr. Relat. Cancer"},{"key":"42659_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00000478-199801000-00007","volume":"22","author":"KJ Busam","year":"1998","unstructured":"Busam, K. J. et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am. J. Surg. Pathol. 22, 57\u201363. https:\/\/doi.org\/10.1097\/00000478-199801000-00007 (1998).","journal-title":"Am. J. Surg. Pathol."},{"key":"42659_CR44","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00129039-200312000-00009","volume":"11","author":"Z Ghorab","year":"2003","unstructured":"Ghorab, Z., Jorda, M., Ganjei, P. & Nadji, M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl. Immunohistochem. Mol. Morphol. 11, 330\u2013333. https:\/\/doi.org\/10.1097\/00129039-200312000-00009 (2003).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"42659_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/jcp.51.2.114","volume":"51","author":"WG McCluggage","year":"1998","unstructured":"McCluggage, W. G., Burton, J., Maxwell, P. & Sloan, J. M. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J. Clin. Pathol. 51, 114\u2013116. https:\/\/doi.org\/10.1136\/jcp.51.2.114 (1998).","journal-title":"J. Clin. Pathol."},{"key":"42659_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1677\/joe.0.1610341","volume":"161","author":"LM Munro","year":"1999","unstructured":"Munro, L. M., Kennedy, A. & McNicol, A. M. The expression of inhibin\/activin subunits in the human adrenal cortex and its tumours. J. Endocrinol. 161, 341\u2013347. https:\/\/doi.org\/10.1677\/joe.0.1610341 (1999).","journal-title":"J. Endocrinol."},{"key":"42659_CR47","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1210\/jc.2010-0653","volume":"95","author":"S Sbiera","year":"2010","unstructured":"Sbiera, S. et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J. Clin. Endocrinol. Metab. 95, E161\u2013E171. https:\/\/doi.org\/10.1210\/jc.2010-0653 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"42659_CR48","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3109\/07435809809032699","volume":"24","author":"J Arola","year":"1998","unstructured":"Arola, J., Liu, J., Heikkila, P., Voutilainen, R. & Kahri, A. Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors. Endocr. Res. 24, 865\u2013867. https:\/\/doi.org\/10.3109\/07435809809032699 (1998).","journal-title":"Endocr. Res."},{"key":"42659_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1677\/joe.0.1650223","volume":"165","author":"J Arola","year":"2000","unstructured":"Arola, J. et al. Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm. J. Endocrinol. 165, 223\u2013229. https:\/\/doi.org\/10.1677\/joe.0.1650223 (2000).","journal-title":"J. Endocrinol."},{"key":"42659_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ecl.2015.02.007","volume":"44","author":"Y Nakamura","year":"2015","unstructured":"Nakamura, Y. et al. Adrenocortical carcinoma: Review of the pathologic features, production of adrenal steroids, and molecular pathogenesis. Endocrinol. Metab. Clin. North Am. 44, 399\u2013410. https:\/\/doi.org\/10.1016\/j.ecl.2015.02.007 (2015).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"42659_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","volume":"228","author":"WE Rainey","year":"2004","unstructured":"Rainey, W. E., Saner, K. & Schimmer, B. P. Adrenocortical cell lines. Mol. Cell. Endocrinol. 228, 23\u201338. https:\/\/doi.org\/10.1016\/j.mce.2003.12.020 (2004).","journal-title":"Mol. Cell. Endocrinol."},{"key":"42659_CR52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.mce.2011.08.041","volume":"351","author":"T Wang","year":"2012","unstructured":"Wang, T. & Rainey, W. E. Human adrenocortical carcinoma cell lines. Mol. Cell. Endocrinol. 351, 58\u201365. https:\/\/doi.org\/10.1016\/j.mce.2011.08.041 (2012).","journal-title":"Mol. Cell. Endocrinol."},{"key":"42659_CR53","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1530\/JOE-10-0493","volume":"209","author":"Y Xing","year":"2011","unstructured":"Xing, Y. et al. The effects of ACTH on steroid metabolomic profiles in human adrenal cells. J. Endocrinol. 209, 327\u2013335. https:\/\/doi.org\/10.1530\/JOE-10-0493 (2011).","journal-title":"J. Endocrinol."},{"key":"42659_CR54","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"Reidy-Lagunes, D. L. et al. Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014A new look at an old drug. Oncologist 22, 1102\u20131106. https:\/\/doi.org\/10.1634\/theoncologist.2016-0459 (2017).","journal-title":"Oncologist"},{"key":"42659_CR55","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189\u20132197. https:\/\/doi.org\/10.1056\/NEJMoa1200966 (2012).","journal-title":"N. Engl. J. Med."},{"key":"42659_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040941","author":"M Lagana","year":"2020","unstructured":"Lagana, M. et al. Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: The Brescia experience. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12040941 (2020).","journal-title":"Cancers (Basel)"},{"key":"42659_CR57","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht, M. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1\u2013G46. https:\/\/doi.org\/10.1530\/EJE-18-0608 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"42659_CR58","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","volume":"156","author":"S Sbiera","year":"2015","unstructured":"Sbiera, S. et al. Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156, 3895\u20133908. https:\/\/doi.org\/10.1210\/en.2015-1367 (2015).","journal-title":"Endocrinology"},{"key":"42659_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/mmr.2012.1244","volume":"7","author":"TP Lehmann","year":"2013","unstructured":"Lehmann, T. P., Wrzesinski, T. & Jagodzinski, P. P. The effect of mitotane on viability, steroidogenesis and gene expression in NCIH295R adrenocortical cells. Mol. Med. Rep. 7, 893\u2013900. https:\/\/doi.org\/10.3892\/mmr.2012.1244 (2013).","journal-title":"Mol. Med. Rep."},{"key":"42659_CR60","doi-asserted-by":"publisher","DOI":"10.3791\/59123","author":"AS Fakhouri","year":"2019","unstructured":"Fakhouri, A. S. & Leight, J. L. Measuring global cellular matrix metalloproteinase and metabolic activity in 3D hydrogels. J. Vis. Exp. https:\/\/doi.org\/10.3791\/59123 (2019).","journal-title":"J. Vis. Exp."},{"key":"42659_CR61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1089\/adt.2018.877","volume":"17","author":"AS Fakhouri","year":"2019","unstructured":"Fakhouri, A. S., Weist, J. L., Tomusko, A. R. & Leight, J. L. High-throughput three-dimensional hydrogel cell encapsulation assay for measuring matrix metalloproteinase activity. Assay Drug Dev. Technol. 17, 100\u2013115. https:\/\/doi.org\/10.1089\/adt.2018.877 (2019).","journal-title":"Assay Drug Dev. Technol."},{"key":"42659_CR62","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1016\/j.biomaterials.2013.06.023","volume":"34","author":"JL Leight","year":"2013","unstructured":"Leight, J. L., Alge, D. L., Maier, A. J. & Anseth, K. S. Direct measurement of matrix metalloproteinase activity in 3D cellular microenvironments using a fluorogenic peptide substrate. Biomaterials 34, 7344\u20137352. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.06.023 (2013).","journal-title":"Biomaterials"},{"key":"42659_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fpubh.2018.00103","volume":"6","author":"SD Forsythe","year":"2018","unstructured":"Forsythe, S. D. et al. Environmental toxin screening using human-derived 3D bioengineered liver and cardiac organoids. Front. Public Health 6, 103. https:\/\/doi.org\/10.3389\/fpubh.2018.00103 (2018).","journal-title":"Front. Public Health"},{"key":"42659_CR64","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08143-8","author":"KI Votanopoulos","year":"2019","unstructured":"Votanopoulos, K. I. et al. Model of patient-specific immune-enhanced organoids for immunotherapy screening: Feasibility study. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-019-08143-8 (2019).","journal-title":"Ann. Surg. Oncol."},{"key":"42659_CR65","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.matbio.2015.01.019","volume":"44\u201346","author":"G Shay","year":"2015","unstructured":"Shay, G., Lynch, C. C. & Fingleton, B. Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 44\u201346, 200\u2013206. https:\/\/doi.org\/10.1016\/j.matbio.2015.01.019 (2015).","journal-title":"Matrix Biol."},{"key":"42659_CR66","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/1471-2407-9-188","volume":"9","author":"A Kohrmann","year":"2009","unstructured":"Kohrmann, A., Kammerer, U., Kapp, M., Dietl, J. & Anacker, J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9, 188. https:\/\/doi.org\/10.1186\/1471-2407-9-188 (2009).","journal-title":"BMC Cancer"},{"key":"42659_CR67","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/modpathol.3800683","volume":"19","author":"M Volante","year":"2006","unstructured":"Volante, M. et al. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod. Pathol. 19, 1563\u20131569. https:\/\/doi.org\/10.1038\/modpathol.3800683 (2006).","journal-title":"Mod. Pathol."},{"key":"42659_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28313","author":"J Che","year":"2022","unstructured":"Che, J. et al. alphaCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. Biotechnol. Bioeng. https:\/\/doi.org\/10.1002\/bit.28313 (2022).","journal-title":"Biotechnol. Bioeng."},{"key":"42659_CR69","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/aca05d","author":"CC Clark","year":"2022","unstructured":"Clark, C. C. et al. Immersion bioprinting of hyaluronan and collagen bioink-supported 3D patient-derived brain tumor organoids. Biomed. Mater. https:\/\/doi.org\/10.1088\/1748-605X\/aca05d (2022).","journal-title":"Biomed. Mater."},{"key":"42659_CR70","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12086-y","author":"SD Forsythe","year":"2022","unstructured":"Forsythe, S. D. et al. Patient-specific sarcoma organoids for personalized translational research: Unification of the operating room with rare cancer research and clinical implications. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-022-12086-y (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"42659_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26871","author":"J Aleman","year":"2018","unstructured":"Aleman, J. & Skardal, A. A multi-site metastasis-on-a-chip microphysiological system for assessing metastatic preference of cancer cells. Biotechnol. Bioeng. https:\/\/doi.org\/10.1002\/bit.26871 (2018).","journal-title":"Biotechnol. Bioeng."},{"key":"42659_CR72","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/sj.bjc.6601594","volume":"90","author":"L Wall","year":"2004","unstructured":"Wall, L., Talbot, D. C., Bradbury, P. & Jodrell, D. I. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br. J. Cancer 90, 800\u2013804. https:\/\/doi.org\/10.1038\/sj.bjc.6601594 (2004).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42659-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:15:49Z","timestamp":1700583349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42659-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42659-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.24.525287","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15508"}}